Bioprocessing of Viral Vaccines
Editat de Amine Kamen, Laura Cerveraen Limba Engleză Paperback – 29 iul 2024
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 412.21 lei 6-8 săpt. | |
CRC Press – 29 iul 2024 | 412.21 lei 6-8 săpt. | |
Hardback (1) | 936.08 lei 3-5 săpt. | +24.75 lei 4-10 zile |
CRC Press – 6 sep 2022 | 936.08 lei 3-5 săpt. | +24.75 lei 4-10 zile |
Preț: 412.21 lei
Preț vechi: 433.90 lei
-5% Nou
Puncte Express: 618
Preț estimativ în valută:
78.89€ • 81.94$ • 65.53£
78.89€ • 81.94$ • 65.53£
Carte tipărită la comandă
Livrare economică 03-17 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781032135519
ISBN-10: 1032135514
Pagini: 328
Ilustrații: 148
Dimensiuni: 156 x 234 mm
Greutate: 0.61 kg
Ediția:1
Editura: CRC Press
Colecția CRC Press
Locul publicării:Boca Raton, United States
ISBN-10: 1032135514
Pagini: 328
Ilustrații: 148
Dimensiuni: 156 x 234 mm
Greutate: 0.61 kg
Ediția:1
Editura: CRC Press
Colecția CRC Press
Locul publicării:Boca Raton, United States
Public țintă
Professional Practice & DevelopmentCuprins
1. Bioprocessing of viral vaccines-Introduction. 2. Introduction to Virology. 3. Principles of immunology. 4. Cell lines for vaccine production. 5. Upstream Processing for Viral Vaccines – General Aspects. 6. Upstream Processing for Viral Vaccines - Process Intensification. 7. Downstream Processing of Viral Vaccines. 8. Analytical, QbD and PAT Applied to Viral Production Processes. 9. Manufacturing of seasonal and pandemic influenza vaccines - a case study. 10. Recombinant vaccines: Gag-based VLPs. 11. Vectored Vaccines. 12. Design and Production of Vaccines Against COVID-19 using Established Vaccine Platforms.
Notă biografică
Amine Kamen is a professor of bioengineering at McGill University, and Canada
Research Chair in bioprocessing of viral vaccines. He is a researcher emeritus of the
National Research Council of Canada (NRC) where he was employed until early
2014, as head of the Process Development section of the Human Health Therapeutics
Portfolio. At NRC, he established one of North America’s largest and most advanced
governmental centers for animal cell culture addressing process development and
scale-up of biologics. Also, he developed with his team and licensed to industry
multiple technology platforms for efficient manufacturing of recombinant proteins
and viral vectors and vaccines and led technology transfer to manufacturing sites for
clinical evaluation and commercialization. His current research activities focus on
uncovering mechanisms associated with cell production of viral vectors and viral
vaccines, cell and metabolic engineering, process control and monitoring, and process
analytical technologies of high-yield productions of viral vectors for gene delivery
and vaccination. He has published over 170 papers in refereed international journals
and acts as a consultant for several national and international private and public
organizations.
Laura Cervera is a Chemical Engineer from Universitat Autònoma de Barcelona
(Barcelona, Spain). After graduating she did her PhD in Biotechnology on the topic
“Strategies for improving production levels of HIV-1 VLPs by transient transfection
of HEK 293 suspension cultures”. Then she moved to McGillUniversity (Montreal,
Canada) to pursue her research on VLP production, this time using Insect cells as a
platform. She came back to Barcelona to join a project on AAV production for gene
therapy applications using HEK 293 cells.
Research Chair in bioprocessing of viral vaccines. He is a researcher emeritus of the
National Research Council of Canada (NRC) where he was employed until early
2014, as head of the Process Development section of the Human Health Therapeutics
Portfolio. At NRC, he established one of North America’s largest and most advanced
governmental centers for animal cell culture addressing process development and
scale-up of biologics. Also, he developed with his team and licensed to industry
multiple technology platforms for efficient manufacturing of recombinant proteins
and viral vectors and vaccines and led technology transfer to manufacturing sites for
clinical evaluation and commercialization. His current research activities focus on
uncovering mechanisms associated with cell production of viral vectors and viral
vaccines, cell and metabolic engineering, process control and monitoring, and process
analytical technologies of high-yield productions of viral vectors for gene delivery
and vaccination. He has published over 170 papers in refereed international journals
and acts as a consultant for several national and international private and public
organizations.
Laura Cervera is a Chemical Engineer from Universitat Autònoma de Barcelona
(Barcelona, Spain). After graduating she did her PhD in Biotechnology on the topic
“Strategies for improving production levels of HIV-1 VLPs by transient transfection
of HEK 293 suspension cultures”. Then she moved to McGillUniversity (Montreal,
Canada) to pursue her research on VLP production, this time using Insect cells as a
platform. She came back to Barcelona to join a project on AAV production for gene
therapy applications using HEK 293 cells.
Descriere
This book focuses on cell culture-produced viral vaccines to meet the needs of the rapidly expanding research and development in academia and industry in the field. This book introduces the basic principles of vaccination and the manufacturing of viral vaccines.